Full Press Release Details
Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa ® (Tucatinib) and Chemotherapy.
ZYME
Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa ® (Tucatinib) and Chemotherapy
Key Takeaway: Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa ® (Tucatinib) and Chemotherapy
Price reaction · baseline $34.07 (2021-07-27 close) · hit after-hours · clean, no other ZYME news in the window
day 0 close
-0.4%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+23%
120-day peak, hindsight
Typical move
5.4%
average across 7 past catalysts
Cash runway
~35 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers